Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2013 by Universitaire Ziekenhuizen Leuven.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Steven Pans, Universitaire Ziekenhuizen Leuven Identifier:
First received: January 26, 2013
Last updated: January 28, 2013
Last verified: January 2013

Whole body MRI with diffusion weighted imaging is a useful imaging tool

  • staging and diagnosis
  • therapy monitoring All patients will be scanned before and during treatment. The findings on diffusion weighted imaging will be correlated to the golden standard (computer tomography and MRI (T1 and STIR)).

Multiple Myeloma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up

Resource links provided by NLM:

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • Validation [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Validation of whole body MRI diffusion-weighted imaging in multiple myeloma at 3 Tesla MRI: correlation of the new MRI imaging technique (diffusion weighted imaging)to standard validated imaging technique (Computer Tomography and Magnetic Resonance Imaging)

Secondary Outcome Measures:
  • Therapy assessment [ Time Frame: 4 years ] [ Designated as safety issue: No ]

    Whole body MRI with Diffusion weighted imaging is useful for treatment monitoring in multiple myeloma patients during and after therapy.

    Measurement of apparent diffusion coefficient (ADC) and comparison of ADC before, during and after therapy. Correlation of ADC with clinical findings and standard MRI findings.

Other Outcome Measures:
  • outcome [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    correlation between early treatment response and outcome of the patient by measuring apparent diffusion coefficient

Estimated Enrollment: 100
Study Start Date: September 2008
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Indolent myeloma patient
Symptomatic Myeloma patient


Ages Eligible for Study:   25 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with clinical and laboratory findings, highly suggestive for multiple myeloma. All patients underwent bone marrow biopsy.

Inclusion Criteria:

  • Patients with clinical and laboratory findings, highly suggestive for multiple myeloma.

Exclusion Criteria:

  • All patients who are not allowed to be scanned on MRI (Pacemaker, implants ed.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01780766

Contact: Steven Pans, MD 3216340505

University Hospitals Leuven Recruiting
Leuven, Belgium
Contact: Steven Pans, MD    3216340505   
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Principal Investigator: Steven Pans, MD Universitaire Ziekenhuizen Leuven
  More Information

Responsible Party: Steven Pans, Medical Doctor Radiologist, Universitaire Ziekenhuizen Leuven Identifier: NCT01780766     History of Changes
Other Study ID Numbers: FIMM  S51079 
Study First Received: January 26, 2013
Last Updated: January 28, 2013
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Universitaire Ziekenhuizen Leuven:
Whole body MRI
Multiple myeloma
Diffusion Weighted MRI
Whole body scan

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Body Weight
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Signs and Symptoms processed this record on October 21, 2016